Cargando…
RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
Immunotherapy has improved the prognosis for many melanoma patients; however, our capacity to predict patient responses and to understand the biological differences between patients who will or will not respond is limited. Gene expression profiling of tumors from patients who respond to immunotherap...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363879/ https://www.ncbi.nlm.nih.gov/pubmed/34388693 http://dx.doi.org/10.1016/j.tranon.2021.101197 |